tafasitamab   Click here for help

GtoPdb Ligand ID: 11131

Synonyms: Minjuvi® | Monjuvi® | MOR-208 | MOR00208 | MOR208 | tafasitamab-cxix | Xmab5574
Approved drug Immunopharmacology Ligand
tafasitamab is an approved drug (FDA (2020), EMA (2021))
Compound class: Antibody
Comment: Tafasitamab (MOR208, formerly Xmab®5574) is a humanized Fc-engineered monoclonal antibody directed against CD19 that was developed by MorphoSys [4]. XmAb® antibodies are designed with modifications in their Fc domain (S239D/I332E mutations) that increase binding to Fcγ receptors on immune cells. This optimises the antibody's Fc-mediated effector function (i.e. antibody-dependent cell-mediated cytotoxicity, ADCC) [1,5]. At the beginning ot 2020, MorphoSys and Incyte Corporation entered into a collaboration and license agreement for the global development and commercialization of tafasitamab (MOR208).
Bioactivity Comments
In a a Raji cell-based competitive binding assay (with Alexa Fluor 647-labelled antibody as probe), tafasitamab binds to CD19 with a pKa of ~9.6 [2]. Tafasitamab (XmAb5574) increases ADCC and antibody-dependent cellular phagocytosis (ADCP) in lymphoma xenograft models [2].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD19 Primary target of this compound Hs Antibody Binding - - - 2
⤷ [2]